Company Filing History:
Years Active: 2014-2017
Title: Matthew Douglas Breyer: Innovator in Therapeutics
Introduction
Matthew Douglas Breyer is a distinguished inventor based in Indianapolis, Indiana. With a remarkable portfolio consisting of two patents, Breyer has made significant contributions to the field of therapeutic methods, particularly in chronic kidney disease.
Latest Patents
Breyer's latest inventions include two significant patents:
1. **Therapeutic uses for VEGFR1 antibodies** - This invention focuses on methods of using VEGFR1 antibodies for the treatment of chronic kidney disease.
2. **Therapeutic uses of soluble alpha-Klotho** - This patent relates to the therapeutic applications of soluble alpha-Klotho, showcasing innovative approaches to addressing health issues.
Career Highlights
Matthew Douglas Breyer is currently employed at Eli Lilly and Company, where he utilizes his expertise in developing advanced therapeutic solutions. His position at a prominent pharmaceutical company highlights his commitment to improving patient care through innovative research.
Collaborations
Throughout his career, Breyer has collaborated with notable colleagues, including Linda Maureen O'Bryan and Rosamund Carol Smith. These partnerships have contributed to the advancement of research within his fields of innovation.
Conclusion
In summary, Matthew Douglas Breyer has established himself as an impactful inventor through his significant contributions to therapeutic technologies. His work at Eli Lilly and Company and the patents he holds are testament to his dedication to advancing healthcare solutions.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.